{
  "id": 9589721,
  "title": "BMO cuts Acadia Pharmaceuticals stock price target on trial miss",
  "url": "https://urgent.news/2026/09/24/bmo-cuts-acadia-pharmaceuticals-stock-price-target-on-trial-miss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-24T17:03:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/bmo-cuts-acadia-pharmaceuticals-stock-price-target-on-trial-miss-93CH-4915926"
  },
  "original_language": "en",
  "account": "BMO Capital reduced its price target on Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) stock to $34, maintaining an Outperform rating. The stock price dropped 7.4% over the past week, trading at $22.93 following the trial results. The firm lowered its probability of success estimate for Acadia's drug candidate from 40% to 35% after the RADIANT trial results. BMO Capital highlighted that the trial miss poses a near-term challenge for Acadia shares. The company's commercial portfolio remains strong due to Nuplazid and Daybue. Acadia generated $1.14 billion in revenue last year, with a market cap of $3.93 billion. Analysts noted a valuation disconnect, even under conservative remlifanserin assumptions, with InvestingPro suggesting the stock is undervalued, offering an average upside potential of 33%. Acadia also announced a preliminary court approval of a settlement in a stockholder derivative action. The Phase 2 results of Acadia's RADIANT study for remlifanserin in Alzheimer’s disease psychosis narrowly missed the primary endpoint but achieved nominal significance on a key secondary endpoint.",
  "summary": null,
  "key_points": [
    "BMO lowers Acadia Pharmaceuticals target to $34, maintains Outperform rating",
    "RADIANT trial results lower success probability from 40% to 35%",
    "Acadia's commercial portfolio strong with Nuplazid and Daybue"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}